pam_columbus — that is really helpful context on 2026 payer coverage. Follow-up question: did you change anything about your diet at the same time?
I am in a similar situation (month 2) and trying to set realistic expectations.
To answer TinaHashiRN's question specifically:
From a clinical standpoint, 2026 payer coverage update is well-supported by the literature.
The short answer: follow the standard titration protocol and reassess at 4-6 weeks.
The longer answer involves pharmacokinetic considerations around steady-state concentrations, which I am happy to elaborate on if helpful.
marcus_mpls — wow. This community is amazing.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemAdding my data to this 2026 payer coverage discussion:
| Metric | Baseline | Month 3 | Month 8 |
|---|---|---|---|
| Weight | 250 lbs | 225 lbs | 195 lbs |
| A1C | 6.4% | 5.8% | 5.4% |
| hsCRP | 4.0 | 2.0 | 0.8 |
Protocol: Semaglutide 2.4mg/wk, resistance training 3x/wk, protein 1.2g/kg/day.
Slightly tangential to 2026 payer coverage but marcus_mpls reminded me — does anyone have experience combining this with metformin?
I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.